206
Participants
Start Date
February 28, 2003
Primary Completion Date
December 31, 2003
Study Completion Date
December 31, 2003
Placebo
Placebo for 15 weeks
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
"2 week up titration (10 mg)~12 weeks stable dose (10 mg)~1 week down titration (10 mg)"
15 mg fampridine-SR (4-aminopyridine, 4-AP)
"10 mg twice daily for 1 week~15 mg twice daily for 14 weeks~2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (15 mg)~1 week down titration (10 mg)"
20 mg fampridine-SR (4-aminopyridine, 4-AP)
"2 week up titration (10 mg x 1 week, 15 mg x 1 week)~12 weeks stable dose (20 mg)~1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
Mt. Sinai School of Medicine - MS Center, New York
Maimonides MS Care Center, Brooklyn
SUNY Stony Brook, Stony Brook
University of Rochester Medical School, Rochester
Thomas Jefferson University, Philadelphia
University of Maryland at Baltimore, Baltimore
Carolinas Medical Center MS Center, Charlotte
Shepherd Center, Atlanta
Ohio State University, Columbus
Cleveland Clinic Foundation, Cleveland
University of Wisconsin Hospital and Clinics, Madison
Fairview MS Center, Minneapolis
University of Chicago, Chicago
Washington University School of Medicine, St Louis
University of Texas-Houston, Houston
Barrow Neurological Institute at St. Joseph Hospital and Medical Center, Phoenix
University of New Mexico, Albuquerque
USC MS Comprehensive Care Center, Los Angeles
Oregon Health Sciences University; MS Center, Portland
Swedish Medical MS Center, Seattle
University of Washington School of Medicine, Seattle
Yale University MS Center, New Haven
Gimbel MS Center, Teaneck
Foothills Medical Centre, Calgary
St. Michael's Hospital, Toronto
Lead Sponsor
Acorda Therapeutics
INDUSTRY